Advertisement

PEN

Penumbra, Inc.

Healthcare · USD

Set alert

Price alert · PEN

All alert types
318.95 USD -3.02 -0.94%
As of Oct 30, 2026 Extended hours 319.01 +0.02%
Bid
318.73 × 40
Ask
319.27 × 40
318.33 Day range 321.83
225.54 52-week range 359.40
YTD
+2.59%
1 year
+37.75%
Open
320.56
Prev close
321.97
Mkt cap
12.56B
Vol
497.75K
Avg vol
342.85K
EPS
4.07
P/E
78.37
Div yield
0.00%
More statistics
Low
318.33
High
321.83
Forward P/E
52.34
Beta
0.70
Short ratio
5.55
Inst. own
88.30%
Dividend
0.00
Ex-div date
Earnings
Feb 24, 2027
50-d avg
320.60
200-d avg
327.46
1y target
362.54

MAX chart

Chart tools
Interval
PEN all-time price chart35.3117.1198.9280.6362.4Oct 15Jan 18Mar 20Jun 22Aug 24Oct 26

Key statistics

Market cap
12.57B
Enterprise value
12.24B
Trailing P/E
78.42
Forward P/E
52.34
PEG ratio
3.63
Price / sales
8.35
Price / book
8.77
EPS (TTM)
4.07
Beta
0.70
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
10.67%
Revenue (TTM)
1.50B
Revenue growth
14.90%
Free cash flow
161.10M
Total cash
658.80M
Total debt
212.71M
Return on equity
11.37%
Shares outstanding
39.39M
Short % of float
6.60%
50-day average
320.60
200-day average
327.46

Analyst view

Consensus: hold

Hold
Price target (mean) 362.54 +13.7% upside
Target (low)
320.00
Target (mean)
362.54
Target (high)
374.00
Ratings (0m) 17 3 buy · 14 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold14
  • Sell0
  • Strong sell0

Next earnings

Feb 24, 2027

Expected Feb 24, 2027. Consensus EPS estimate 1.48.

Earnings history

Financials — quick view

All financials
PEN Revenue — quarterly 410.14M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN Net income — quarterly 42.28M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN EPS — quarterly 1.07
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PEN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20261.44———
Oct 29, 2026Sep 30, 20261.201.07-0.13-10.83%
Jul 30, 2026Jun 30, 20261.160.88-0.28-24.14%
May 6, 2026Mar 31, 20261.040.82-0.22-21.15%
Feb 25, 2026Dec 31, 20251.111.18+0.07+6.31%
Nov 5, 2025Sep 30, 20250.9290.97+0.04+4.41%

Upgrades / downgrades

PEN analyst upgrades and downgrades
DateFirmActionFromTo
Jul 6, 2026Evercore ISI GroupmainOutperformOutperform
Jun 11, 2026RBC CapitalreitSector PerformSector Perform
May 7, 2026CitigroupmainNeutralNeutral
May 7, 2026Evercore ISI GroupmainOutperformOutperform
Feb 26, 2026Evercore ISI GroupmainOutperformOutperform
Jan 20, 2026RBC CapitaldownOutperformSector Perform

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on PEN — it syncs with the Stock Master app.

Insider holders

PEN insider holders
InsiderRelationLatest transactionDateShares held
BOSE ARANIDirectorStock Award(Grant)Feb 12, 2026259,609
ELSESSER ADAMChief Executive OfficerStock GiftMay 18, 20260
GREWAL HARPREET SINGHDirectorSaleApr 1, 20268,719
KASSING DON WDirectorStock Award(Grant)Feb 13, 20259,909
LEEDS JANETDirectorStock Award(Grant)Feb 12, 20266,639
NARAYAN SHRUTHIPresidentStock Award(Grant)Aug 16, 202633,880

Institution ownership

PEN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.91%4,297,5551.37BJun 29, 2026
HBK Investments L P4.67%1,838,508586.81MJun 29, 2026
Vanguard Capital Management LLC4.34%1,709,877545.75MJun 29, 2026
Vanguard Portfolio Management LLC4.23%1,667,276532.15MJun 29, 2026
State Street Corporation3.16%1,243,258396.82MJun 29, 2026
ExodusPoint Capital Management, LP2.77%1,090,430348.04MJun 29, 2026

Fund ownership

PEN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,403,042447.82MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.01%1,186,100378.57MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.17%856,690273.43MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.26%494,387157.80MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%450,774143.88MJun 29, 2026
SmallCap World Fund Inc1.05%412,644131.71MSep 29, 2026
Advertisement